Broken String Biosciences

INDUCE-seq™ is a game changing #technology for development of advanced #therapies, but what is it? Watch this video to learn how the platform precisely characterises breaks in the #genome, to inform the development of cutting edge therapeutics that are safer by design!🧪

By bringing INDUCE-seq® in-house, researchers gain faster insights, regulatory confidence, and real-time guide selection—a game-changer for gene editing safety. Enrollment is limited—apply here: brokenstringbio.com/resources/cata… #GeneEditing #Biotech #CRISPR

We’re thrilled to launch the Catalyst program, our Early Access initiative that brings INDUCE-seq® directly into gene editing labs. Now, therapy developers can detect on- and off-target effects in days instead of months—accelerating development while ensuring safety.

Great to see Park-based @BrokenStringBio highlighted in the @Clarivate 'Companies to Watch: Next Generation Gene Editing' report. You can download the full report here - ow.ly/zEkq50UCCNC

This recognition inspires us to continue delivering impactful solutions for the next generation of genomic advancements. Read the full article here: lnkd.in/ewB-N3kY

Read the full article here: lnkd.in/ewB-N3kY

We are thrilled to be recognized for our role in shaping the future of genomic medicine by @pharmavoice. Our cutting-edge technologies provide vital insights for therapy developers, ensuring safety, efficacy, and scalability in the ever-evolving gene-editing landscape.

Being recognized as a key player in this prestigious list underscores our commitment to redefining genomic safety and shaping the future of cell and gene therapies.

We're thrilled to be featured in Clarivate’s Companies to Watch: Next Generation Gene Editing 2024 report! clarivate.com/life-sciences-…

This coming week, our Director of Alliance Management and CCO will be attending the Cell & Gene Meeting on the Mesa in Phoenix, AZ, from October 7-9, 2024! # We’re excited to engage in meaningful discussions & explore collaboration opportunities! See you there! #CGMESA24

ICYMI, our Co-founder and CSO, Simon Reed, Ph.D. discusses the current challenges in off-target gene editing and explores what the future holds for safer, more effective therapies. To watch the webinar on-demand, you may register here: lnkd.in/ecNCjeWV #GeneEditing

Broken String Biosciences: Laurence Reid and Brad Crutchfield healthinvestor.co.uk/executive_move… #healthcare @BrokenStringBio @laurence_reid @Regeneron @ThirdRockV @Alnylam @10xGenomics @QIAGEN @illumina @BioRad

Park-based @BrokenStringBio has strengthened its Board with two new appointments - Laurence Reid, as Chairman, and Brad Crutchfield as Non-Executive Director. Full story - ow.ly/YHKO50Tw3gR

Today @BrokenStringBio announced the appointments of Laurence Reid, as Chairman, and Brad Crutchfield as Non-Executive Director of its Board of Directors. Read more: rb.gy/t801oi #PressRelease #CellandGene

Their combined expertise in biotech and life sciences will be crucial as we continue to advance INDUCE-seq and drive growth in the cell and gene therapy industry. Read the full announcement here: brokenstringbio.com/broken-string-…

Exciting News! We’re delighted to welcome Laurence Reid, Ph.D. as Chairman and Brad Crutchfield as Non-Executive Director to our Board of Directors.

If you are looking for a highly sensitive assay for off-target detection in your gene-edited cell or gene therapy programs, simply email us on partnerships@brokenstringbio.com.

If you are looking for a highly sensitive assay for off-target detection in your gene-edited cell or gene therapy programs, simply message us at partnerships@brokenstringbio.com.

INDUCE-seq® can identify DNA double strand breaks without the need for DNA amplification, thus greatly increasing sensitivity and signal to noise ratio.

Broken String Biosciences Appoints Steve Becker as Chief Commercial Officer impactnews-wire.com/broken-string-… @BrokenStringBio

Steve's leadership will be pivotal as we enhance our offerings in the cell and gene therapy market, ensuring transformative treatments become a safe reality for patients worldwide. Read more here: brokenstringbio.com/broken-string-…

We are thrilled to welcome Steve Becker as our Chief Commercial Officer. With over 30 years of experience in the global life sciences industry and a stellar track record, Steve will spearhead the commercialization of our pioneering DNA break-mapping platform, INDUCE-seq®.